Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039025 | 1.00 | PIK3CD (0.47) | PIK3CDHRH3KCNA3KDM4EALDH1A1 | |
| SCHEMBL3419549 | 0.92 | PIK3CD (0.41) | PIK3CDHRH3KCNA3KDM4EALDH1A1 | |
| SCHEMBL15133968 | 0.86 | PIK3CD (0.45) | PIK3CDKCNA3KDM4ECYP2D6 | |
| SCHEMBL6629183 | 0.86 | PIK3CD (0.45) | PIK3CDKCNA3KDM4ECYP2D6 | |
| SCHEMBL13923638 | 0.86 | PIK3CD (0.45) | PIK3CDKCNA3KDM4ECYP2D6 | |
| SCHEMBL16311405 | 0.84 | SLC6A3 (0.38) | HRH3KCNA3KDM4EALDH1A1GAA | |
| SCHEMBL24361844 | 0.82 | KCNA3 (0.37) | HRH3KCNA3KDM4EALDH1A1TDP1 | |
| SCHEMBL357156 | 0.82 | DPP4 (0.38) | HRH3KCNA3KDM4EALDH1A1TDP1 | |
| SCHEMBL357157 | 0.82 | DPP4 (0.38) | HRH3KCNA3KDM4EALDH1A1TDP1 | |
| SCHEMBL24607412 | 0.82 | KCNA3 (0.37) | HRH3KCNA3KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-RE50030-E1 | Methods to treat lymphoplasmacytic lymphoma | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-2024100139-A1 | USE OF IFN-I ACTIVITY AS A BIOMARKER FOR TLR INHIBITOR TREATMENT | MERCK PATENT GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| US-11911392-B2 | Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-27 | — | — | US | disclosed |
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834447-B2 | Indole derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023194458-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2023-10-12 | — | — | WO | disclosed |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-10-05 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1755593-B1 | NAPHTHALENE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | MCARTHUR SILVIA G | 2007-11-15 | — | — | US | disclosed |
| US-7259158-B2 | Naphthaline derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HOFFMAN-LA ROCHE INC. | 2006-01-12 | — | — | US | disclosed |
| EP-0974602-B1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR CORP (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6291596-B1 | CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT | JSR CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265254-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | PIK3CD 3905/4885HRH3 1/4885KCNA3 1579/4885 |
| US-11834447-B2 | Indole derivatives and use thereof | TRPC4, TRPV4, TRPV1 | PIK3CD 4445/4885HRH3 659/4885KCNA3 118/4885 |
| US-20230312498-A1 | NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS | MAPK1, MAPK8, MAPK4 | PIK3CD 558/4885HRH3 3554/4885KCNA3 4613/4885 |
| US-11911392-B2 | Non-catalytic substrate-selective p38α-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | MAPK1, MAPK15, MAPK8 | PIK3CD 1774/4885HRH3 4053/4885KCNA3 4750/4885 |
| US-20060009449-A1 | Naphthaline derivatives as H3 inverse agonists | HRH3, HRH4, HRH1 | PIK3CD 3905/4885HRH3 1/4885KCNA3 1579/4885 |
| US-11780823-B2 | Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors | WNT1, WNT3, WNT3A | PIK3CD 843/4885HRH3 1885/4885KCNA3 2895/4885 |
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | PIK3CD 366/4885HRH3 3666/4885KCNA3 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.